L
Logos Global Management, L.P.
+ HoldingMANE
+17.53%
3M Return
$97.930
-3.731 (-3.81%)Al cierre
Loading chart…
- High
- 102.410
- Open
- 102.300
- VWAP
- 99.11
- Vol
- 623.70K
- Mkt Cap
- —
- Low
- 96.995
- Amount
- 61.82M
- EV/EBITDA, TTM
- 0.00
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
AI analysis of Veradermics Inc (MANE)
buyVeraDermics, Inc. (MANE) is a good buy right now due to its recent positive trial results for its hair loss treatment, which led to a 12% stock increase. The current price is $97.93, significantly lower than analyst targets, with Citi setting a target of $160 and B. Riley at $170, suggesting substantial upside potential. However, the company has reported increasing net losses, with a net income of -30,011,000 USD in Q1 2026, which poses a risk to investors.
Métricas de valoración
The current forward P/E ratio for Veradermics Inc (MANE) is 0.00, compared to its 5-year average forward P/E of .
Whales holding MANE
Cronología de eventos
Noticias
9.008-11NewsfilterVDPHL01 Shows Promising Results for Female Hair Loss Treatment
8.507-18NASDAQ.COMMultiple Biopharma Companies Receive FDA Approvals
- 9.007-17Newsfilter
Veradermics Presents Phase 2/3 Data for VDPHL01 in Hair Loss Treatment
2.007-16NASDAQ.COMBiotech Stocks Surge Amid Positive Developments
8.507-15stocktwitsVeradermics Reports Positive Results for Female Hair Loss Treatment
MANE FAQ — answered by Alphio AI
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL. It operates in the Healthcare sector.
VeraDermics, Inc. (MANE) is a good buy right now due to its recent positive trial results for its hair loss treatment, which led to a 12% stock increase. The current price is $97.93, significantly lower than analyst targets, with Citi setting a target of $160 and B. Riley at $170, suggesting substantial upside potential. However, the company has reported increasing net losses, with a net income of -30,011,000 USD in Q1 2026, which poses a risk to investors.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.